title: [Clinical significance of CD4+CD25+ T cells in peripheral blood of patients in systemic lupus erythematosus].
abstract: OBJECTIVE
  To investigate the expressions of C(4)D(+)CD(25)(+) T cells in the peripheral blood of patients with systemic lupus erythematosus (SLE) and to identify the relationship between the levels of CD(4)(+)CD(25)(+) T cells and the disease activity and progression of SLE.
  
  
  METHODS
  Fifty-three SLE patients were enrolled in the study. Flow-cytometric assay was employed for detection of CD(4)(+)CD(25)(+) T cells and CD(4)(+)CD(25)(bright) T cells were defined according to fluorescence intensity of CD(25) expression exceeding 100. Meanwhile, correlation analysis was performed between their expression and the scores of SLE disease active index (SLEDAI), C(3), dsDNA and antinuclear antibody titles.
  
  
  RESULTS
  The levels of peripheral blood CD(4)(+)CD(25)(+) T cells in SLE were (7.84 +/- 1.85)%, which were significantly lower than those in a group of healthy control [(9.18 +/- 2.01)%, P < 0.05]. The levels of CD(4)(+)CD(25)(+) T cells in a group of active SLE [(6.72 +/- 1.16)%] were higher than those in a group of stable SLE [(8.57 +/- 1.91)%, P < 0.01]. There was no difference between the active and stable groups of SLE in peripheral blood CD(4)(+)CD(25)(bright) T cells [(0.85 +/- 0.24)% vs (0.91 +/- 0.25)%, P = 0.686], but they were significantly lower than those in the group of healthy controls [(1.43 +/- 1.08)%, P < 0.01]. With the reduction of the SLEDAI scores in SLE patients after relevant treatment, the levels of peripheral blood CD(4)(+)CD(25)(bright) T cells did not change. No correlation was found between the levels of CD(4)(+)CD(25)(bright) T cells and SLEDAI scores, antinuclear antibody titles, dsDNA and C(3), respectively (rho = -0.188, P = 0.178; rho = -0.216, P = 0.121; rho = 0.082, P = 0.560; rho = 0.010, P = 0.944).
  
  
  CONCLUSIONS
  The reduction of CD(4)(+)CD(25)(+) T cells in peripheral blood may participate in the pathogenesis of SLE.
authors.affiliation: Department of Rheumatology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China. hangzhouyxy@zj.com
authors.forename: Xu-yan
authors.initials: XY
authors.lastname: Yang
authors.forename: Xiao-yong
authors.initials: XY
authors.lastname: Lu
authors.forename: Dong-hang
authors.initials: DH
authors.lastname: Xü
authors.forename: Qing-hua
authors.initials: QH
authors.lastname: Lü
authors.forename: Qiao-hong
authors.initials: QH
authors.lastname: Wang
authors.forename: Hua-xiang
authors.initials: HX
authors.lastname: Wu
mesh_terms: D000293:Adolescent; D000328:Adult; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology*; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D015375:Receptors, Interleukin-2 / Q000097:blood / Q000276:immunology*; D012720:Severity of Illness Index
chemical_list: D015375:Receptors, Interleukin-2